Melbourne, Sep 22, 2009 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful completion of enrolment of the second group of 20 patients randomised to receive an increased dose of Revascor(TM), the proprietary allogeneic, or “off-the-shelf”, universal adult stem cell product for congestive heart failure.
